Clinical Trial Update: A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease [Phase 2]

View source ↗

Summary

A long-term extension study of AL002 in Alzheimer's disease was terminated, and the study results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AL002

Snippet

Sponsor: Alector Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2026-02-25